Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study

Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study

Erythrodermic psoriasis (EP) is a rare but severe form of psoriasis. Conventional treatments are often ineffective and challenging to maintain; however, new biologic medications have shown promise in the management of EP with limited evidence. To assess the efficacy and safety of two biological trea...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yachen Wang, Rishna Malla, Fengling Yang, Hanjing Yin, Suju Luo
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-07-01
Series:	Indian Journal of Dermatology
Subjects:	adalimumab biological agents erythrodermic psoriasis psoriasis secukinumab
Online Access:	https://journals.lww.com/10.4103/ijd.ijd_1051_23
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series
by: Andrea D'Arino, et al.
Published: (2025-07-01)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Complete treatment experience on psoriasis patients with secukinumab in real practice in Krasnodar region
by: L. S. Kruglova, et al.
Published: (2021-06-01)

Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach
by: Xu JM, et al.
Published: (2025-07-01)

Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab
by: Yu K, et al.
Published: (2025-01-01)

Erythrodermic Psoriasis in the Context of Emerging Triggers: Insights into Dupilumab-Associated and COVID-19-Induced Psoriatic Disease
by: Aya Fadel, et al.
Published: (2025-06-01)

Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing
by: Karine Rodriguez-Fernandez, et al.
Published: (2024-12-01)

Efficacy of Secukinumab in Management of Erythrodermic Psoriasis: A Study in Treatment-naïve Cases
by: Aradhana Rout, et al.
Published: (2025-07-01)

Experience of using secukinumab in the treatmentof patients with psoriasis
by: N. V. Zilberberg, et al.
Published: (2021-11-01)

Secukinumab: In psoriasis and beyond
by: Aditya K. Bubna, et al.
Published: (2025-01-01)

Successful treatment of generalized pustular psoriasis during pregnancy with secukinumab in a patient hypersensitive to spesolimab: a case report
by: Shuang Zhang, et al.
Published: (2025-12-01)

Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
by: Matteo Megna, et al.
Published: (2022-07-01)

Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery
by: Leyla S. Namazova-Baranova, et al.
Published: (2023-11-01)

Clinical efficacy of secukinumab in treating sleep disorders in psoriatic patients
by: ZHOU Cuimei, et al.
Published: (2025-07-01)

Secukinumab treatment of IgA nephropathy manifested by psoriasis complicated with nephrotic syndrome： a case report
by: Xie Ting-ting, et al.
Published: (2025-03-01)

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab
by: Angela Fico, et al.
Published: (2025-05-01)

Secukinumab: A safe option to treat psoriasis and psoriatic arthritis in the presence of interstitial lung disease
by: Raja Natarajan
Published: (2019-01-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021-05-01)

Secukinumab treatment of IgA nephropathy manifested by psoriasis complicated with nephrotic syndrome： a case report
by: Xie Ting-ting, et al.
Published: (2025-03-01)

Awareness of the Risk of Paradoxical Psoriasis in Patients with SAPHO Syndrome Undergoing Treatment with Secukinumab: A Case Series
by: Xu C, et al.
Published: (2025-03-01)

Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY)
by: Hideto Kameda, et al.
Published: (2025-03-01)

Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis
by: Xiao Y, et al.
Published: (2025-07-01)

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy
by: Marco May Lee, et al.
Published: (2025-07-01)

Case Report: Secukinumab for the treatment of severe psoriasis in a patient with hereditary hemochromatosis
by: Yingzhe Yu, et al.
Published: (2025-08-01)

Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023)
by: Yingdong Wang, et al.
Published: (2024-12-01)

Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study
by: Lu Xing, et al.
Published: (2025-12-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
by: Ploysyne Rattanakaemakorn, et al.
Published: (2024-11-01)

THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
by: Elena Yurievna Loginova, et al.
Published: (2010-06-01)

Fractional Carbon Dioxide Laser Combined with Secukinumab in the Treatment of Refractory Psoriasis Lesions on the Lower Legs
by: Ye H, et al.
Published: (2024-12-01)

Dual Biologic Therapy for Psoriasis in a Patient with Atopic Dermatitis
by: Ma L, et al.
Published: (2025-04-01)

Superior effect of adalimumab versus secukinumab on ultrasound-confirmed synovitis in psoriatic arthritis: comprehensive evidence from musculoskeletal ultrasound and clinical assessments
by: Yiyi Wang, et al.
Published: (2024-12-01)

Results of direct comparison of the clinical efficacy of ixekizumab and adalimumab: data from the SPIRIT H2H study
by: T. V. Korotaeva
Published: (2020-09-01)

Disease-Modifying Treatment of Psoriasis in Children
by: Nikolay N. Murashkin, et al.
Published: (2024-11-01)

Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition
by: Huiling Dai, et al.
Published: (2025-07-01)

Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trials
by: Vibeke Strand
Published: (2025-06-01)

RESULTS OF EVALUATING THE EFFICACY OF SECUKINUMAB VERSUS ADALIMUMAB IN TREATING PSORIATIC ARTHRITIS BY USING THE MATCHING-ADJUSTED INDIRECT COMPARISON METHOD
by: T. V. Korotaeva
Published: (2016-12-01)

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
by: David M. Pariser, et al.
Published: (2025-03-01)

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial
by: Selma Atalay, et al.
Published: (2022-07-01)

Hepatotoxicity Induced by Adalimumab in Chronic Plaque Psoriasis Patient: A Case Report
by: Algarzae NK, et al.
Published: (2025-07-01)